Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feedernews.abbvie.com
Press Releases | AbbVie Newsroom
Get the latest updates from Press Releases | AbbVie Newsroom directly as they happen.
Follow now 241 followers
Latest posts
Last updated 5 months ago
Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine
5 months ago
NORTH CHICAGO, Ill., Nov. 16, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today...
Natrelle® Unveils New "For Every BODY" Campaign
5 months ago
IRVINE, Calif., Nov. 8, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company...
BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before
6 months ago
IRVINE, Calif., Nov. 1, 2023 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company...
AbbVie Reports Third-Quarter 2023 Financial Results
6 months ago
NORTH CHICAGO, Ill., Oct. 27, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial...
Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines
6 months ago
–All primary and secondary endpoints were met for both Phase 3 studies...
Allergan Aesthetics Supports Breast Cancer Patients and Celebrates Breast Reconstruction Patients Through The Reblossom Project
6 months ago
IRVINE, Calif., Oct. 19, 2023 /PRNewswire/ -- Yesterday, on Breast Reconstruction Awareness...
AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints
6 months ago
NORTH CHICAGO, Ill., Oct. 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today...
AbbVie Announces Upadacitinib (RINVOQ®) Met the Primary Endpoint in Phase 2 Clinical Trial of Vitiligo as Program Advances to Phase 3
6 months ago
NORTH CHICAGO, Ill., Oct. 11, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today...
AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ (upadacitinib) in Adults and Adolescents with Moderate to Severe Atopic Dermatitis
6 months ago
NORTH CHICAGO, Ill., Oct. 11, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today...
AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023
6 months ago
– Late-breaking data from a head-to-head study evaluating SKYRIZI® (risankizumab) versus STELARA®...
AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline
7 months ago
- Mitokinin's lead compound, a selective PINK1 activator, is designed to address...
Nature Publishes Discovery and Preclinical Results for ABBV-CLS-484, a Potential First-in-Class PTPN2/N1 Inhibitor in Cancer Immunotherapy
7 months ago
NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., Oct. 4, 2023 /PRNewswire/...